Modality profile: Bi-Specifics and cytokines at #ASCO23
- blonca9
- Jun 3, 2023
- 1 min read
Updated: Jun 15, 2023
Xencor CEO Bassil Dahiyat walks us through the idea behind bi-specific antibodies and cytokines in cancer research.
Also look for unique social pages for BiotechTV U.
Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.